PATENT CLAIM ANALYSIS

Application Number: 16060641
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "210210"]

Abstract:
The present invention relates to LpxC antibacterial compounds of Formula (IA): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

Claim (Index 6):
The compound of Formula (II) according to  claim 4  which is: Ex. Compound Name Chemical Structure 11 (2R)-4-[7-(2,6-difluorophenyl)-4-oxo-3,4- dihydroquinazolin-3-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   12 (2R)-4-[7-(1,3-dihydro-2-benzofuran-5-yl)-4- oxo-3,4-dihydroquinazolin-3-yl]-N-hydroxy- 2-methanesulfonyl-2-methylbutanamide    13 (2R)-4-[6-fluoro-7-(4-methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin-3-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   14 (2R)-4-[8-fluoro-7-(4-methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin-3-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   15 (2R)-4-[6-fluoro-7-(4-methylphenyl)-4-oxo- 3,4-dihydroquinazolin-3-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   16 (2R)-4-[5-fluoro-7-(4-methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin-3-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   17 (2R)-4-[5-fluoro-7-(4-methylphenyl)-4-oxo- 3,4-dihydroquinazolin-3-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   20 (2R)-4-(6-fluoro-7-{4-[(morpholin-4- yl)methyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   21 (2R)-4-(6-fluoro-7-{4-[2-(morpholin-4- yl)ethyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   22 (2R)-4-[7-(4- {[cyclopropyl(methyl)amino]methyl}phenyl)- 6-fluoro-4-oxo-3,4-dihydroquinazolin-3-yl]-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   23 (2R)-4-[6-fluoro-7-(2-fluoro-4-{[(2- methoxethyl)(methyl)amino]methyl}phenyl)- 4-oxo-3,4-dihydroquinazolin-3-yl]-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   24 (2R)-4-(7-{2,3-difluoro-4-[2-(3- methoxyazetidin-1-yl)ethyl]phenyl}-6-fluoro- 4-oxo-3,4-dihydroquinazolin-3-yl)-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   25 (2R)-4-(7-{4-[(cyclopropylamino)methyl]-2- fluorophenyl)-6-fluoro-4-oxo-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   26 (2R)-4-(6-fluoro-7-{2-fluoro-4-[(morpholin-4- yl)methyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   27 (2R)-4-{6-fluoro-7-[2-fluoro-4-(2- hydroxyethyl)phenyl]-4-oxo-3,4- dihydroquinazolin-3-yl}-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   28 (2R)-4-{6-fluoro-7-[4-(2- hydroxyethyl)phenyl]-4-oxo-3,4- dihydroquinazolin-3-yl}-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   29 (2R)-N-hydroxy-2-methanesulfonyl-2- methyl-4-(8-methyl-7-{4-[(morpholin-4- yl)methyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)butanamide   30 (2R)-4-[6-fluoro-7-(6-methoxypyridin-3-yl)-4- oxo-3,4-dihydroquinazolin-3-yl]-N-hydroxy- 2-methanesulfonyl-2-methylbutanamide    31 (2R)-4-(6-fluoro-4-oxo-7-phenyl-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   32   (2R)-4-[7-(1,3-dihydro-2-benzofuran-5-yl)-6- fluoro-4-oxo-3,4-dihydroquinazolin-3-yl]-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   33 (2R)-4-{7-[6-(dimethylamino)pyridin-3-yl]-6- fluoro-4-oxo-3,4-dihydroquinazolin-3-yl}-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   34 2-(4-{6-fluoro-3-[(3R)-3-(hydroxycarbamoyl)- 3-methanesulfonyl-3-methylpropyl]-4-oxo- 3,4-dihydroquinazolin-7-yl}phenyl)ethyl acetate   35 (2R)-N-hydroxy-2-methanesulfonyl-2- methyl-4-(7-{4-[(morpholin-4- yl)methyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)butanamide   36 (2R)-4-[7-(2-fluoro-4-{[(2- methoxyethyl)(methyl)amino]methyl}phenyl)- 4-oxo-3,4-dihydroquinazolin-3-yl]-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   37 (2R)-4-(7-{2-fluoro-4-[(morpholin-4- yl)methyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   38 (2R)-4-[7-(2,3-difluoro-4-{[(2- methoxyethyl)(methyl)amino]methyl}phenyl)- 4-oxo-3,4-dihydroquinazolin-3-yl]-N- hydroxy-2-methanesulfonyl-2- methylbutanamide   39 (2R)-4-[7-(4- {[cyclopropyl(methyl)amino]methyl}-3- fluorophenyl)-4-oxo-3,4-dihydroquinazolin-3- yl]-N-hydroxy-2-methanesulfonyl-2- methylbutanamide   40 (2R)-4-(7-{4-[(3,3-difluoroazetidin-1- yl)methyl]-2-fluorophenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   41 (2R)-4-(7-{4-[(cyclopropylamino)methyl]-2- fluorophenyl}-4-oxo-3,4-dihydroquinazolin-3- yl)-N-hydroxy-2-methanesulfonyl-2- methylbutanamide   42 (2R)-N-hydroxy-2-methanesulfonyl-2- methyl-4-(7-{4-[2-(morpholin-4- yl)ethyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)butanamide   43 (2R)-4-(7-{2-fluoro-4-[2-(morpholin-4- yl)ethyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- ethanesulfonyl-2-methylbutanamide   44 (2R)-N-hydroxy-4-{7-[4-(2- hydroxyethyl)phenyl]-4-oxo-3,4- dihydroquinazolin-3-yl}-2-methanesulfonyl- 2-methylbutanamide   45 (2R)-4-{7-[2-fluoro-4-(2- hydroxyethyl)phenyl]-4-oxo-3,4- dihydroquinazolin-3-yl}-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   46 (2R)-4-[7-(4-ethoxyphenyl)-4-oxo-3,4- dihydroquinazolin-3-yl]-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   47 (2R)-N-hydroxy-2-methanesulfonyl-4-{7-[4- (methoxymethyl)phenyl]-4-oxo-3,4- dihydroquinazolin-3-yl}-2-methylbutanamide   48 (2R)-4-{7-[2-fluoro-4-(2- methoxyethyl)phenyl]-4-oxo-3,4- dihydroquinazolin-3-yl}-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   49 (2R)-4-[7-(3-fluoro-4- {[methoxy(methyl)amino]methyl}phenyl)-4- oxo-3,4-dihydroquinazolin-3-yl]-N-hydroxy- 2-methanesulfonyl-2-methylbutanamide   50 (2R)-4-(7-{2-fluoro-4- [(methoxyamino)methyl]phenyl}-4-oxo-3,4- dihydroquinazolin-3-yl)-N-hydroxy-2- methanesulfonyl-2-methylbutanamide   51 (2R)-4-(7-{4-[(ethoxyamino)methyl]-2- fluorophenyl)-4-oxo-3,4-dihydroquinazolin-3- yl)-N-hydroxy-2-methanesulfonyl-2- methylbutanamide   52 (2R)-N-hydroxy-2-methanesulfonyl-4-[7-(4- {[methoxy(methyl)amino]methyl}phenyl)-4- oxo-3,4-dihydroquinazolin-3-yl]-2- methylbutanamide or a pharmaceutically acceptable salt thereof

Metadata:
- Claim Count in Document: 56.0
- Percentile: 94.0
- Lexical Diversity: 1.10526
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14004105', '14068956', '14154239', '13515607', '14110165']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7820278596914326
- 35 USC 102 Novelty (BERT): 0.5504927619191959
- Combined Prediction Score: 0.758874349914209
- Mean Citation Score: 356.35282599999994
- Max Citation Score: 394.587
- Similarity Product: 315.9977683521509

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test